Viking Therapeutics
VKTX
Market cap $7.16B

64.61 USD

-1.24

1.88%

At close Oct 17, 4:00 PM EDT

After hours

64.70

+0.09

0.14%

1 day

-1.88%

5 days

2.91%

1 month

2.65%

3 months

29.63%

6 months

-2.80%

Year to date

253.45%

1 year

502.71%

5 years

864.33%

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 30

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

104% more call options, than puts

Call options by funds: $321M | Put options by funds: $157M

60% more repeat investments, than reductions

Existing positions increased: 162 | Existing positions reduced: 101

24% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 75

5% more funds holding

Funds holding: 366 [Q1] → 384 (+18) [Q2]

1.08% less ownership

Funds ownership: 73.93% [Q1] → 72.85% (-1.08%) [Q2]

36% less capital invested

Capital invested by funds: $6.63B [Q1] → $4.26B (-$2.37B) [Q2]

54% less funds holding in top 10

Funds holding in top 10: 13 [Q1] → 6 (-7) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$80

24%

upside

Avg. target

$104

60%

upside

High target

$138

114%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 91 / 255 met price target	39%upside $90	Buy Reiterated	9 Oct 2024
Oppenheimer Jay Olson 31% 1-year accuracy 15 / 49 met price target	114%upside $138	Outperform Reiterated	25 Sept 2024
Morgan Stanley Michael Ulz 31% 1-year accuracy 5 / 16 met price target	63%upside $105	Overweight Reiterated	12 Sept 2024
JP Morgan Hardik Parikh 50% 1-year accuracy 2 / 4 met price target	24%upside $80	Overweight Initiated	11 Sept 2024
Raymond James Steven Seedhouse 43% 1-year accuracy 9 / 21 met price target	83%upside $118	Strong Buy Maintained	25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 26 articles about VKTX published over the past 30 days

The Motley Fool

Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future

Viking recently announced the results of an early-stage clinical trial for VK0214.

Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future

Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024

Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024.

Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024

Zacks Investment Research

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

The Motley Fool

Where Will Viking Therapeutics Be in 5 Years?

We could be witnessing the birth of a major player in the biotech industry.

Where Will Viking Therapeutics Be in 5 Years?

The Motley Fool

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics

It's hard to go wrong with either company, but one is more appealing.

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics

The Motley Fool

The Ultimate Biotech Stock to Buy With $100 Right Now

This company is operating in one of today's hottest markets.

The Ultimate Biotech Stock to Buy With $100 Right Now

Zacks Investment Research

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALD

Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage.

Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALD

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with X-linked adrenoleukodystrophy (X-ALD). Results from this study showed VK0214 to be safe and well-tolerated following once-daily dosing over the 28-day study period.

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

The Motley Fool

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts

See News Rankings

Charts implemented using Lightweight Charts™